December 25, 2025
StemRIM Inc.

StemRIM Announces Completion of Patient Enrollment in the Global Phase 2b Clinical Trial of the Redasemtide for Acute Ischemic Stroke

Osaka, Japan, December 25, 2025 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; "StemRIM" or "Company") announces that Shionogi & Co., Ltd. (Head Office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Isao Teshirogi; hereinafter "Shionogi") has informed us that patient enrollment has been completed in the global Phase 2b clinical trial (hereinafter "the Trial") of the peptide drug (development code: S-005151), created from our out-licensed "Regeneration-Inducing Medicine™" candidate Redasemtide (HMGB1 peptide), targeting patients with acute ischemic stroke.

The Trial is being conducted in 18 countries worldwide, including Japan, the United States, and countries in Europe, and targets adult patients aged 18 years or older who have experienced acute ischemic stroke within 25 hours of onset. The objective of the Trial is to evaluate the efficacy and safety of Redasemtide versus placebo in both the cohort not receiving endovascular recanalization therapy and the cohort receiving such therapy. The primary endpoint is the modified Rankin Scale (mRS) at 90 days after the initiation of study drug administration, which serves as a key indicator of clinical efficacy.

This matter is progressing as planned and will have no impact on our full-year financial results for the fiscal year ending July 2026.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called “Regeneration-Inducing Medicine™”. The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. “Regeneration-Inducing Medicine™” is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from “Regeneration-Inducing Medicine™” include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
X: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)